121 results about "ScFv Antibodies" patented technology

The present invention features improved in vitro RNA display libraries to allow reliable expression and selection of scFv antibody molecules from expression libraries. The scFv antibody libraries of the invention contain an optimized, shortened inter-domain linker that improves expression scFv antibody expression. The scFv antibody libraries also include short nucleic acid barcodes that allow for identification of individual library clones, libraries or subsets thereof. Primers for generating, amplifying and spectratyping the scFv antibody libraries of the invention are also provided.

Compositions including an antibody single-chain variable fragment (scFv) conjugate that specifically binds to ROR1 tumor-associated antigen are provided. The anti-ROR1 scFv antibody and conjugates may include a biologically-active molecule. Such conjugates may comprise a chimeric receptor to direct T cells to respond to ROR1 cancer cells, Methods to use the scFV conjugates to target cells expressing ROR1 for therapeutic and diagnostic purposes are also provided.

The present invention concerns CAR, CAR-T and CAR-NK constructs, preferably comprising a scFv antibody fragment against a disease-associated antigen or a hapten. More preferably, the antigen is a TAA, such as Trop-2. The constructs may be administered to a subject with a disease, such as cancer, autoimmune disease, or immune dysfunction disease, to induce an immune response against disease-associated cells. Where the constructs bind to a hapten, the subject is first treated with a hapten-conjugated antibody that binds to a disease associated antigen. Therapy may be supplemented by other treatments, such as debulking procedures (e.g., surgery, chemotherapy, radiation therapy) or coadministration of other agents. More preferably, administration of the construct is preceded by predosing with an unconjugated antibody that binds to the same disease-associated antigen. Most preferably, an antibody against CD74 or HLA-DR is administered to reduce systemic immunotoxicity induced by the constructs.

The present invention features improved methods of in vitro RNA display to allow reliable expression and selection of scFv antibody molecules from expression libraries. The improved methods, in part, involve the use of mildly reducing conditions, which favor of scFv intra-chain disulphide bond and thus correct folding of the scFv antibody molecules. Although particularly suited to expression and selection of scFv antibody molecules, the methods of the invention are also expedient for in vitro RNA display of all classes of protein.

Compositions are provided, which can be used as frameworks for the creation of very stable and soluble single-chain Fv antibody fragments. These frameworks have been selected for intracellular performance and are thus ideally suited for the creation of scFv antibody fragments or scFv antibody libraries for applications where stability and solubility are limiting factors for the performance of antibody fragments, such as in the reducing environment of a cell. Such frameworks can also be used to identify highly conserved residues and consensus sequences which demonstrate enhanced solubility and stability.

The present invention relates to improved antibodies against tumor surface antigens and their use in the treatment of tumors. Of particular interest are highly stable, humanized, high affinity antibodies against carcinoembryonic antigen (CEA), especially the antibody we have termed sm3E, which is derived from the scFv antibody MFE-23. Such antibodies have the potential for improved therapeutic efficacy.

The invention discloses a full-human anti-EGFR scFv antibody segment and entire antibody, which contains heavy chain of antibody and nucleic acid and amino acid of variable area of light chain as well as high-effective expressing method of entire antibody in the CHO cell.

The invention provides scFv antibodies and monoclonal antibodies that neutralize SARS-CoV. Also provided are methods of treating and/or preventing a coronavirus-related disease or disorder such as SARS. The invention also provides methods of vaccinating a patient against SARS-CoV. Also provided are methods of diagnosing coronavirus-related diseases or disorders and methods of detecting the presence of a coronavirus in a sample. The invention additionally provides methods of screening for compounds that modulate the binding of SARS-CoV and the SARS-CoV receptor ACE2 as well as for compounds useful to treat SARS-CoV-related diseases or disorders.

The invention provides methods of using sequence based analysis and rational strategies to modify and improve the structural and biophysical properties of immunobinders, and in particular of single chain antibodies (scFvs), including such properties as stability, solubility, and/or antigen binding affinity. The invention provides methods of engineering immunobinders, and in particular scFvs, by performing one or more substitutions at amino acid positions identified by analysis of a database of selected, stable scFv sequences, wherein preferred amino acid residues for substitution have been identified. The invention also provides immunobinders prepared according to the engineering methods of the invention. The invention also provides preferred scFv framework scaffolds, into which CDR sequences can be inserted, as well as scFv antibodies made using these preferred framework scaffolds.

The invention belongs to the technical field of biology, and relates to a camel source immunity nanometer antibody (single-domain heavy-chain antibody, VHH) specifically bound with AFP and application of the antibody. The amino acid sequence of the antibody is SEQ ID NO.:1. The invention further relates to nucleotides for encoding amino acids. The AFP nanometer antibody can be used as the antibody to be applied to immunological detection of AFP not for disease diagnosis and treatment. Compared with a Scfv antibody and a Fab antibody, the camel source immunity VHH has the higher specificity and affinity, more stable in structure, resistant to acid, base and high temperature, high in detection flexibility and the like, so that the immunity detection stability is greatly improved, and meanwhile the environment resistance is greatly improved.

The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNF-mediated disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.

The present technology provides methods and compositions for the treatment of tissue-damage related immune dysregulation by administering a composition comprising one or more of CD24; CD24 fragments, variants and derivatives, CD24Fc fusion proteins; HMBG1-binding proteins, binding proteins to HMBG1 Box B; antagonists of HMGB1, polyclonal, monoclonal, recombinant, chimeric, humanized scFv antibodies and antibody fragments to HMGB1 or fragments of HMGB1 and antibodies that bind and suppress the activity of HMGB1 Box B; Siglec 10 agonists such as anti-Siglec 10 antibodies; and combinations thereof to a patient.

The invention discloses two types of ScFv (Single Chain Variable Fragment) antibodies, encoding genes of the antibodies and applications of the antibodies for preparing the preparations for treating or preventing infectious bursal disease of chicken. Two single-chain antibodies (namely, the ScFv antibodies) are provided; and the ScFv antibodies can be specially bound with the protein 2 (VP2) (Virus Protein 2) in an IBDV (Infectious Bursal Disease Virus) structure and a plurality of IBDV strains to block the cytopathic effect (CPE) of the chicken embryo fibroblast by the IBDV so as to protect the young chicken infected with IBDV. The immune serum and egg yolk antibody are tedious in preparation, high in production cost, unstable in effect, difficult to control industrialized production quality, capable of causing horizontal disease spread and the like in a use process; the ScFv antibodies disclosed by the invention can overcome the above disadvantages and have the advantages of strong specificity, good treatment effect, controllable industrialized production quality, capability of preventing the horizontal disease spread caused by the egg yolk antibody and the like; and therefore, by virtue of the ScFv antibodies, a new situation is opened up in the IBDV prevention and treatment history, and even in the entire prevention and treatment history for animal virus diseases.

The invention discloses a human single-chain antibody fragment (scFv) antibody of anti-recombination basic fibroblast growth factor and an application thereof. An amino acid sequence of heavy chain variable area of the human scFv antibody is shown in SEQ ID NO. 1, and an amino acid sequence of light chain variable area of the human scFv antibody is shown in SEQ ID NO. 2. A gene sequence encoding the heavy chain variable area is shown in SEQ ID NO. 3. A gene sequence encoding the light chain variable area is shown in SEQ ID NO. 4. The human scFv antibody has the characteristics of high affinity and specificity, and can be directly developed to be used as an antibody drug for human because the human scFv antibody is fully human antibody. The gene encoding the human scFv antibody can be constructed and expressed to obtain various forms of micromolecular genetic engineering antibodies, such as, fragment antigen-binding (Fab) antibody, F(ab)2, single chain antibody, Nanobody, antibody fusion protein, immunoglobulin G (IgG) complete antibody, etc., which can be used for preparing antibody drugs for diagnosing and treating tumor and/or inhibiting viscera fibrosis.

The invention provides human scFv antibodies and monoclonal antibodies that neutralize influenza virus. Also provided are methods of treating and/or preventing a influenza related disease or disorder such bird flu The invention also provides methods of vaccinating a patient against influenza. Also provided are methods of diagnosing influenza-related diseases or disorders and methods of detecting the presence of a influenza in a sample.

The invention relates to an anti-DON single-chain antibody ScFv and a preparing method and application thereof, belonging to biological product field. In the invention, variable region gene Fab section of heavy chain and light chain of antibody is cloned through a PCR method in a hybridoma cell strain McGill078 which secretes anti-DON monoclonal antibody; two genes are recombined through a gene engineering method; a prokaryotic expression plasmid vector is constructed and is transformed to Escherichia coli to express an ScFv antibody active fragment which can specifically recognize DON; and then the recombined single chain antibody ScFv is purified and renatured. The anti-DON recombined single-chain antibody ScFv has an activity for binding with DON and has the advantage of residual detection for DON owing to recognition and binding activity to DON and having antibody medicament prospect for treating DON poisoning after humanized modification; and the constructed transformation vector plasmid is easy to preserve and produce in a great quantity.

This invention relates to immunoglobulin molecules comprising light chain (VL) chimeric variable domains, heavy chain (VH) chimeric variable domains, e.g., scFv antibodies that are expressed at high levels within a host cell, preferably within particular cellular compartments such as, e.g., cytosol or apoplast. The VL, VH and scFv antibody molecules comprise framework scaffolds of particularly preferred framework regions. This invention also relates to nucleic acid molecules encoding the immunoglobulin molecules of this invention, vectors expressing the immunoglobulin molecules, hosts transformed with the nucleic acid molecules and vectors, and methods of using the immunoglobulin molecules. Also described are immunoglobulin libraries as well as host cells, including transgenic plants, expressing the VL, VH or scFv antibody molecules of this invention.